Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults

Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults

Abstract Introduction Adintrevimab is a fully human immunoglobulin G1 extended half-life monoclonal antibody that was developed to have broad neutralization against SARS-CoV, SARS-CoV-2, and other SARS-like CoVs with pandemic potential. Here we report the safety, pharmacokinetics (PK), serum viral n...

Full description

Bibliographic Details
Main Authors: Pete Schmidt, Jean Gong, Kristin Narayan, Deepali Gupta, Frank Engler, Yong Li, Amanda Copans, Ed Campanaro
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-04-01
Series:Infectious Diseases and Therapy
Subjects:
ADG20
Adintrevimab
COVID-19
First in human
Monoclonal antibody
Pharmacokinetics
Online Access:https://doi.org/10.1007/s40121-023-00794-1

Internet

https://doi.org/10.1007/s40121-023-00794-1

Similar Items